Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MAIA Biotechnology, Inc. (MAIA)
NYSE MKT:MAIA
RESEARCH TOOLSreports
Holding MAIA?
Track your performance easily
MAIA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.82 - $5.99
Previous Close$2.23
Volume96.23K
Average Volume (3M)131.32K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$8.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 06, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding25,332,069
10 Day Avg. Volume273,827
30 Day Avg. Volume131,322
Standard Deviation0.27
R-Squared0.00314
Alpha0.00323
Financial Highlights & Ratios
Price to Book (P/B)37.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$14.00Price Target Upside551.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
MAIA Biotechnology, Inc. News
PremiumCompany Announcements
MAIA Biotechnology Reveals Promising Phase 2 Trial Results
PremiumCompany Announcements
MAIA Biotechnology Advances with Clinical Trials and Partnerships
PremiumCompany Announcements
MAIA Biotechnology Reports Progress in Cancer Drug Development
PremiumCompany Announcements
MAIA Biotechnology Highlights Clinical Progress and Investor InsightsOwnership Overview
16.17% Insiders
2.87% Mutual Funds
2.02% Other Institutional Investors
76.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MAIA FAQ
What was MAIA Biotechnology, Inc.’s price range in the past 12 months?
MAIA Biotechnology, Inc. lowest stock price was $0.82 and its highest was $5.99 in the past 12 months.
What is MAIA Biotechnology, Inc.’s market cap?
Currently, no data Available
When is MAIA Biotechnology, Inc.’s upcoming earnings report date?
MAIA Biotechnology, Inc.’s upcoming earnings report date is Nov 06, 2024 which is 16 days ago.
How were MAIA Biotechnology, Inc.’s earnings last quarter?
MAIA Biotechnology, Inc. released its earnings results on Aug 19, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.085.
Is MAIA Biotechnology, Inc. overvalued?
According to Wall Street analysts MAIA Biotechnology, Inc.’s price is currently Undervalued.
Does MAIA Biotechnology, Inc. pay dividends?
MAIA Biotechnology, Inc. does not currently pay dividends.
What is MAIA Biotechnology, Inc.’s EPS estimate?
MAIA Biotechnology, Inc.’s EPS estimate is -$0.36.
How many shares outstanding does MAIA Biotechnology, Inc. have?
MAIA Biotechnology, Inc. has 25,332,070 shares outstanding.
What happened to MAIA Biotechnology, Inc.’s price movement after its last earnings report?
MAIA Biotechnology, Inc. reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went up 3.922%.
Which hedge fund is a major shareholder of MAIA Biotechnology, Inc.?
Currently, no hedge funds are holding shares in MAIA
---
MAIA Biotechnology, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (551.16% Upside)
$14.00 (551.16% Upside)
Blogger Sentiment
Bullish
MAIA Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
89.78%
12-Months-Change
Fundamentals
Return on Equity
-1188.16%
Trailing 12-Months
Asset Growth
32.02%
Trailing 12-Months
Company Description
MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
---
MAIA Stock 12 Month Forecast
Average Price Target
$14.00
▲(551.16% Upside)
Technical Analysis
Best Analysts Covering MAIA
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+4.47%
reiterated a buy rating 2 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +4.47% per trade.
---